This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Coming of Age

Hubert T. Greenway, Jr, MD; Roger C. Cornell, MD

Arch Dermatol. 1990;126(8):1080-1082.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The discovery and naming of interferon by Isaacs and Lindenmann¹ has led to the establishment of a new field of research involving virology, immunology, tumor destruction, cell biology, and molecular genetics, as well as other disciplines. The bearers of interference (interferons) constitute a class of glycoproteins exhibiting antitumor, antiviral, and immunologic properties. Three types of interferons are currently recognized: interferon alfa (alpha leukocyte interferon), interferon beta (fibroblast interferon), and interferon gamma (immune interferon). All three types of interferon have specific structures with interferon alfa and beta being most closely related. Multiple subtypes exist for interferon alfa and several for interferon beta.

In this issue of the ARCHIVES, Edwards and coworkers² demonstrate the antitumor effect of interferon alfa-2b in a sustained release formulation for the treatment of basal cell carcinomas. Two treatment regimens were utilized: a single injection of 10 million IU and a similar regimen (10 million IU) given . . . [Full Text PDF of this Article]

Author Affiliations
From the Scripps Clinic and Research Foundation, Division of Dermatology, La Jolla, Calif.

Footnotes
Accepted for publication June 29, 1990.

Reprint requests to Scripps Clinic and Research Foundation, Division of Dermatology, 10666 N Torrey Pines Rd, La Jolla, CA 92037 (Dr Greenway).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?